Moreover, this similar phenotype was also observed in the previous work, showing that FTO deficiency aggravates ulcerative colitis progression and lower FTO expression in ulcerative colitis patients may enhance their response to vedolizumab treatment.55 These findings together suggest the novel role of demethylase FTO regulates the disruption of arsenic-induced intestinal microenvironment. The gene discussed is FTO; the disease is ulcerative colitis.